Cholinesterase inhibitors reduce cortical Aβ in dementia with Lewy bodies

Neurology

Volumn 68, Issue 20, 2007, Pages 1726-1729

  Ballard, C G ^a   Chalmers, K A ^b   Todd, C ^c   McKeith, I G ^c   O'Brien, J T ^c   Wilcock, G ^b   Love, S ^b   Perry, E K ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b FRENCHAY HOSPITAL   (United Kingdom)

^c NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RIVASTIGMINE; TACRINE; TAU PROTEIN;

ARTICLE; AUTOPSY; BRAIN CORTEX; BRAIN LEVEL; BRAIN TISSUE; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; DRUG EFFECT; FEMALE; HUMAN; HUMAN TISSUE; MALE; NEUROPATHOLOGY; PARENCHYMA; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PROTEIN; AUTOPSY; CEREBRAL CORTEX; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS; COHORT STUDIES; DRUG EVALUATION; FEMALE; GALANTAMINE; HUMANS; INDANS; LEWY BODY DISEASE; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PHENYLCARBAMATES; PIPERIDINES; PROSPECTIVE STUDIES; TACRINE; TAU PROTEINS; TAUOPATHIES;

EID: 34248572114     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000261920.03297.64     Document Type: Article

References (10)

1. Tiraboschi P, Hansen LA, Alford M, et al. Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease. Arch Gen Psychiatry 2002;59:946-951.
2. Perry EK, Curtis M, Dick DJ, et al. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985;48:413-421.
3. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-2518.
4. McKeith I, Mintzer J, Aarsland D, et al. Dementia with Lewy bodies. Lancet Neurol 2004;3:19-28.
5. Verhoeff NP. Acetylcholinergic neurotransmission and the beta-amyloid cascade: implications for Alzheimer's disease. Expert Rev Neurother 2005;5:277-284.
6. Hashimoto M, Kazui H, Matsumoto K, Nakano Y, Yasuda M, Mori E. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? Am J Psychiatry 2005;162:676-682.
7. Hock C, Maddalena A, Raschig A, et al. Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease. Amyloid 2003;10:1-6.
8. Perry EK, Kilford L, Lees AJ, Burn DJ, Perry RH. Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol 2003;54:235-238.
9. Chalmers KA, Culpan D, Kehoe PG, Wilcock GK, Hughes A, Love S. APOE promoter, ACE1 and CYP46 polymorphisms and beta-amyloid in Alzheimer's disease. Neuroreport 2004;15:95-98.
10. Ono K, Hasegawa K, Yamada M, Naiki H. Nicotine breaks down preformed Alzheimer's beta-amyloid fibrils in vitro. Biol Psychiatry 2002;52:880-886.